• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»CSF biomarkers

Could Fujirebio’s pTau 217 CSF assay become a new standard in Alzheimer’s research?

By Pallavi Madhiraju on January 28, 2026   Medical Devices & Diagnostics  

Could Fujirebio’s pTau 217 CSF assay become a new standard in Alzheimer’s research?

Find out how Fujirebio’s new Lumipulse pTau 217 CSF assay could shape the future of Alzheimer’s biomarker research and platform-based diagnostics.

Recent Posts

  • Why Encompass Health is betting on a fast-growing Texas suburb before rivals crowd in
  • What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts
  • Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
  • Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering
  • Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
  • Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
  • Could Actio’s KCNT1 epilepsy drug become an ultra-rare disease test case for the FDA?
  • Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data
  • How Zifo’s AI authoring platform could reshape clinical and CMC documentation
  • INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy
  • Pharma has a Hispanic engagement problem. Relevant+ thinks Healthy Vibras can fix it
  • What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes